A rare point mutation in the Ras oncogene in hepatocellular carcinoma

Surgery Today

Volumn 43, Issue 3, 2013, Pages 289-292

  Taketomi, Akinobu ^a   Shirabe, Ken ^a   Muto, Jun ^a   Yoshiya, Shohei ^a   Motomura, Takashi ^a   Mano, Yohei ^a   Ikegami, Tohru ^a   Yoshizumi, Tomoharu ^a   Sugio, Kenji ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Mutation; Ras; Sorafenib

Indexed keywords

ASPARAGINE; GLYCINE;

ADULT; AGED; ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; POINT MUTATION; POLYMERASE CHAIN REACTION; SOMATIC MUTATION; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CODON; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 84878483955     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-012-0462-8     Document Type: Article

References (17)

1. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76.
2. Okita K. Clinical aspects of hepatocellular carcinoma in Japan. Intern Med. 2006;45:229-33.
3. Taketomi A, Kitagawa D, Itoh S, Harimoto N, Yamashita Y, Gion T, et al. Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute's experience with 625 patients. J Am Coll Surg. 2007;204:580-7.
4. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531-7.
5. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200.
6. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312-27.
7. Abou Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-300.
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
9. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res. 1992;52:2903-6.
10. Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T, Terada M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res. 1989;80:196-9.
11. Tanaka S, Arii S. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. Int J Clin Oncol. 2010;15:235-41.
12. Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, et al. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011;2:e150.
13. Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 2009;7:41.
14. Tada M, Omata M, Ohto M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res. 1990;50:1121-4.
15. Ogata N, Kamimura T, Asakura H. Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology. 1991;13:31-7.
16. Challen C, Guo K, Collier JD, Cavanagh D, Bassendine MF. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol. 1992;14:342-6.
17. Leon M, Kew MC. Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks. Anticancer Res. 1995;15:859-61.